Back

Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Anique Ducharme

Montreal Heart Institute, Montreal (Canada)

6 More presentations in this session

Presentation thumbnail
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction
Mr K. Berg-Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis
Associate Professor A. Cipriani (Padua, IT)
Abstract Slides Video
Presentation thumbnail
The efficacy and tolerability of finerenone related to the use and dosage of diuretics at baseline in FINEARTS-HF
Doctor M. Chimura (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
thumbnail
Congress Presentation
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources